Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease (scientific article published on 31 August 2017)

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Q29617157

Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy

Q30441653

Liver stiffness: a novel parameter for the diagnosis of liver disease

Q30445527

The feasibility and reliability of transient elastography using Fibroscan®: a practice audit of 2335 examinations

Q33810066

Histopathology of nonalcoholic fatty liver disease

Q34306736

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease

Q34758973

Safety and effectiveness of blind percutaneous liver biopsy: analysis of 1412 procedures

Q35819904

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

Q35893923

Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease

Q36047930

Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease

Q36795373

Transjugular liver biopsy--indications, adequacy, quality of specimens, and complications--a systematic review

Q36846542

The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease

Q36880302

Transjugular liver biopsy: comparison of sample adequacy with the use of two automated needle systems

Q37824950

FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice

Q38218609

Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

Q39283211

Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.

Q41042091

Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study

Q41073361

Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis.

Q42212445

Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration

Q42272013

Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis

Q43500799

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

Q45209585

Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations

Q46078112

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).

Q46857868

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

Q51442516

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

Q51541188

Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes.

Q51655382

Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy.

Q51714520

Comparison between the M and XL probes for liver fibrosis assessment by transient elastography.

Q53560566

Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases

Q57705532

Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients

Q57735452

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

Q58622754

Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index

Q58803242

Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C

Q61764154

The Diagnostic Accuracy of Transient Elastography for the Diagnosis of Liver Fibrosis in Bariatric Surgery Candidates with Suspected NAFLD

Q61882116

Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group

Q72036552

Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

Q82648058

Pathology of nonalcoholic fatty liver disease

Q83094715

Final results of a long-term, clinical follow-up in fatty liver patients

Q84384267

Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease

Q87406034

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

metabolic dysfunction–associated steatotic liver disease

Q1546498

P304

page(s)

134-144

P577

publication date

2017-08-31

P1433

published in

Hepatology

Q15724398

P1476

title

Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease

P478

volume

Reverse relations

cites work (P2860)

Q58799831	A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care
Q104568218	Accuracy of Controlled Attenuation Parameter and Liver Stiffness Measurement in Patients with Non-alcoholic Fatty Liver Disease
Q94570307	Applications and Limitations of Noninvasive Methods for Evaluating Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Q92328365	Berberis aristata, Elaeis guineensis and Coffea canephora Extracts Modulate the Insulin Receptor Expression and Improve Hepatic Steatosis in NAFLD Patients: A Pilot Clinical Trial
Q45070782	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.
Q91600205	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
Q90185187	Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease
Q89575741	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
Q97682178	Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
Q88286212	Hepatic Steatosis Assessment with Ultrasound Small-Window Entropy Imaging
Q90091780	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels
Q90580674	Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care
Q89600297	Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant
Q57818077	Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations
Q89123381	Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants
Q91695771	Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study
Q92521100	Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness
Q89074070	Non-alcoholic fatty liver disease and the interface between primary and secondary care
Q45942296	Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.
Q48170451	Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.
Q90284023	Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD
Q90838428	PRO: This Patient Should Have a Liver Biopsy
Q64987408	Past, present and future perspectives in nonalcoholic fatty liver disease.
Q90584983	Predicting Metabolic Syndrome With Machine Learning Models Using a Decision Tree Algorithm: Retrospective Cohort Study
Q59328825	Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables
Q92531772	Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients
Q94475611	Road to identifying endpoint biomarkers in the treatment of nonalcoholic steatohepatitis: are we there yet?
Q58579670	The XL probe: A luxury or a necessity? Risk stratification in an obese community cohort using transient elastography
Q90674610	Validation of a New Point Shear-Wave Elastography Method for Noninvasive Assessment of Liver Fibrosis: A Prospective Multicenter Study
Q93015330	Work up of fatty liver by primary care physicians, review